Barry PharmD - Heron Therapeuti Chairman CEO
| HRTX Stock | USD 2.47 0.42 20.49% |
Insider
Barry PharmD is Chairman CEO of Heron Therapeuti
| Age | 67 |
| Address | 100 Regency Forest Drive, Cary, NC, United States, 27518 |
| Phone | 844 437 6611 |
| Web | https://www.herontx.com |
Heron Therapeuti Management Efficiency
The company has return on total asset (ROA) of (0.0316) % which means that it has lost $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.42 in 2025, whereas Return On Tangible Assets are likely to drop (0.06) in 2025. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 25.3 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 14.8 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| MSc MBA | Inozyme Pharma | 53 | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| MA MS | Inozyme Pharma | N/A | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 67 | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Alexandra HughesWilson | Mereo BioPharma Group | 54 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Lukas Flatz | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0316 |
Heron Therapeuti Leadership Team
Elected by the shareholders, the Heron Therapeuti's board of directors comprises two types of representatives: Heron Therapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heron. The board's role is to monitor Heron Therapeuti's management team and ensure that shareholders' interests are well served. Heron Therapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heron Therapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Executive Officer | ||
| Barry PharmD, Chairman CEO | ||
| Lisa Peraza, VP Officer | ||
| Chris Storgard, Chief Officer | ||
| Kimberly Manhard, Independent Director | ||
| Sean Ristine, Vice President - Human Resources | ||
| Michael Mathews, Senior Vice President - Pain Franchise | ||
| Jeff JD, Assistant Director | ||
| John Poyhonen, Independent Director | ||
| Thomas Ottoboni, Senior Vice President - Pharmaceutical and Preclinical Research and Development | ||
| Brett Fleshman, Chief Officer | ||
| David Szekeres, Senior Vice President General Counsel, Business Development, Corporate Secretary | ||
| Ira Duarte, Executive CFO | ||
| Ryan Craig, Vice Marketing | ||
| Craig Collard, CEO Director | ||
| Jeff Cohn, Assistant Director | ||
| Robert Sullivan, Senior Operations |
Heron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heron Therapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0316 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 492.63 M | ||||
| Shares Outstanding | 152.1 M | ||||
| Shares Owned By Insiders | 0.86 % | ||||
| Shares Owned By Institutions | 76.81 % | ||||
| Number Of Shares Shorted | 30.77 M | ||||
| Price To Earning | (5.15) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.